Sin­ga­pore biotech startup fo­cuses on fi­bro­sis re­search

BioSpectrum (Asia) - - Start-Up-News -

Re­search into key driv­ers of fi­bro­sis will be used by a Sin­ga­pore-funded biotech­nol­ogy start-up, En­le­ofen Bio, to pos­si­bly de­velop first-in-class ther­a­peu­tics for pul­monary fi­bro­sis (PF) and other fi­bro­sis-re­lated dis­eases.

The in­tel­lec­tual prop­erty that came from the work per­formed at two Sin­ga­pore in­sti­tu­tions, DukeNUS Med­i­cal School (DukeNUS) and Na­tional Heart Cen­tre Sin­ga­pore (NHCS), was li­censed to En­le­ofen Bio.

In their joint work, sci­en­tists in­ves­ti­gated new genes im­por­tant for fi­bro­sis in or­der to bet­ter un­der­stand the dis­ease’s bi­ol­ogy and to po­ten­tially dis­cover new drug tar­gets. Be­sides be­ing ev­i­dent at high lev­els on fi­brob­last cul­tures, IL-11 was found by the re­searchers to be an im­por­tant player in col­la­gen de­po­si­tion and fi­brob­last ac­ti­va­tion, two fea­tures of fi­brotic pro­cesses.

Mov­ing such bench find­ings into clin­i­cal work was en­cour­aged and sup­ported by Duke-NUS, NHCS and the Na­tional Health In­no­va­tion Cen­tre of Sin­ga­pore to sup­port the re­search and as­sist in the devel­op­ment of ther­a­peu­tic ap­pli­ca­tions with a com­mer­cial use.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.